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Abstract
The 1000 Genomes Project set out to provide a comprehensive description of common human 
genetic variation by applying whole-genome sequencing to a diverse set of individuals from 
multiple populations. Here we report completion of the project, having reconstructed the genomes 
of 2,504 individuals from 26 populations using a combination of low-coverage whole-genome 
sequencing, deep exome sequencing, and dense microarray genotyping. We characterized a broad 
spectrum of genetic variation, in total over 88 million variants (84.7 million single nucleotide 
polymorphisms (SNPs), 3.6 million short insertions/deletions (indels), and 60,000 structural 
variants), all phased onto high-quality haplotypes. This resource includes >99% of SNP variants 
with a frequency of >1% for a variety of ancestries. We describe the distribution of genetic 
variation across the global sample, and discuss the implications for common disease studies.
The 1000 Genomes Project has already elucidated the properties and distribution of common 
and rare variation, provided insights into the processes that shape genetic diversity, and 
advanced understanding of disease biology1,2. This resource provides a benchmark for 
surveys of human genetic variation and constitutes a key component for human genetic 
studies, by enabling array design3,4, genotype imputation5, cataloguing of variants in regions 
of interest, and filtering of likely neutral variants6,7.
In this final phase, individuals were sampled from 26 populations in Africa (AFR), East 
Asia (EAS), Europe (EUR), South Asia (SAS), and the Americas (AMR) (Fig. 1a; see 
Supplementary Table 1 for population descriptions and abbreviations). All individuals were 
sequenced using both whole-genome sequencing (mean depth = 7.4×) and targeted exome 
sequencing (mean depth = 65.7×). In addition, individuals and available first-degree 
relatives (generally, adult offspring) were genotyped using high-density SNP microarrays. 
This provided a cost-effective means to discover genetic variants and estimate individual 
genotypes and haplotypes1,2.
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Data set overview
In contrast to earlier phases of the project, we expanded analysis beyond bi-allelic events to 
include multi-allelic SNPs, indels, and a diverse set of structural variants (SVs). An 
overview of the sample collection, data generation, data processing, and analysis is given in 
Extended Data Fig. 1. Variant discovery used an ensemble of 24 sequence analysis tools 
(Supplementary Table 2), and machine-learning classifiers to separate high-quality variants 
from potential false positives, balancing sensitivity and specificity. Construction of 
haplotypes started with estimation of long-range phased haplotypes using array genotypes 
for project participants and, where available, their first degree relatives; continued with the 
addition of high confidence bi-allelic variants that were analysed jointly to improve these 
haplotypes; and concluded with the placement of multi-allelic and structural variants onto 
the haplotype scaffold one at a time (Box 1). Overall, we discovered, genotyped, and phased 
88 million variant sites (Supplementary Table 3). The project has now contributed or 
validated 80 million of the 100 million variants in the public dbSNP catalogue (version 141 
includes 40 million SNPs and indels newly contributed by this analysis). These novel 
variants especially enhance our catalogue of genetic variation within South Asian (which 
account for 24% of novel variants) and African populations (28% of novel variants).
To control the false discovery rate (FDR) of SNPs and indels at <5%, a variant quality score 
threshold was defined using high depth (>30×) PCR-free sequence data generated for one 
individual per population. For structural variants, additional orthogonal methods were used 
for confirmation, including microarrays and long-read sequencing, resulting in FDR<5% for 
deletions, duplications, multi-allelic copy-number variants, Alu and L1 insertions, and <20% 
for inversions, SVA (SINE/VNTR/Alu) composite retrotransposon insertions and NUMTs8 
(nuclear mitochondrial DNA variants). To evaluate variant discovery power and genotyping 
accuracy, we also generated deep Complete Genomics data (mean depth = 47×) for 427 
individuals (129 mother–father–child trios, 12 parent–child duos, and 16 unrelateds). We 
estimate the power to detect SNPs and indels to be >95% and >80%, respectively, for 
variants with sample frequency of at least 0.5%, rising to >99% and >85% for frequencies 
>1% (Extended Data Fig. 2). At lower frequencies, comparison with >60,000 European 
haplotypes from the Haplotype Reference Consortium9 suggests 75% power to detect SNPs 
with frequency of 0.1%. Furthermore, we estimate heterozygous genotype accuracy at 
99.4% for SNPs and 99.0% for indels (Supplementary Table 4), a threefold reduction in 
error rates compared to our previous release2, resulting from the larger sample size, 
improvements in sequence data accuracy, and genotype calling and phasing algorithms.
A typical genome
We find that a typical genome differs from the reference human genome at 4.1 million to 5.0 
million sites (Fig. 1b and Table 1). Although >99.9% of variants consist of SNPs and short 
indels, structural variants affect more bases: the typical genome contains an estimated 2,100 
to 2,500 structural variants (~1,000 large deletions, ~160 copy-number variants, ~915 Alu 
insertions, ~128 L1 insertions, ~51 SVA insertions, ~4 NUMTs, and ~10 inversions), 
affecting ~20 million bases of sequence.
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The total number of observed non-reference sites differs greatly among populations (Fig. 
1b). Individuals from African ancestry populations harbour the greatest numbers of variant 
sites, as predicted by the out-of-Africa model of human origins. Individuals from recently 
admixed populations show great variability in the number of variants, roughly proportional 
to the degree of recent African ancestry in their genomes.
The majority of variants in the data set are rare: ~64 million autosomal variants have a 
frequency <0.5%, ~12 million have a frequency between 0.5% and 5%, and only ~8 million 
have a frequency >5% (Extended Data Fig. 3a). Nevertheless, the majority of variants 
observed in a single genome are common: just 40,000 to 200,000 of the variants in a typical 
genome (1–4%) have a frequency <0.5% (Fig. 1c and Extended Data Fig. 3b). As such, we 
estimate that improved rare variant discovery by deep sequencing our entire sample would at 
least double the total number of variants in our sample but increase the number of variants in 
a typical genome by only ~20,000 to 60,000.
Putatively functional variation
When we restricted analyses to the variants most likely to affect gene function, we found a 
typical genome contained 149–182 sites with protein truncating variants, 10,000 to 12,000 
sites with peptide-sequence-altering variants, and 459,000 to 565,000 variant sites 
overlapping known regulatory regions (untranslated regions (UTRs), promoters, insulators, 
enhancers, and transcription factor binding sites). African genomes were consistently at the 
high end of these ranges. The number of alleles associated with a disease or phenotype in 
each genome did not follow this pattern of increased diversity in Africa (Extended Data Fig. 
4): we observed ~2,000 variants per genome associated with complex traits through 
genome-wide association studies (GWAS) and 24–30 variants per genome implicated in rare 
disease through ClinVar; with European ancestry genomes at the high-end of these counts. 
The magnitude of this difference is unlikely to be explained by demography10,11, but instead 
reflects the ethnic bias of current genetic studies. We expect that improved characterization 
of the clinical and phenotypic consequences of non-European alleles will enable better 
interpretation of genomes from all individuals and populations.
Sharing of genetic variants among populations
Systematic analysis of the patterns in which genetic variants are shared among individuals 
and populations provides detailed accounts of population history. Although most common 
variants are shared across the world, rarer variants are typically restricted to closely related 
populations (Fig. 1a); 86% of variants were restricted to a single continental group. Using a 
maximum likelihood approach12, we estimated the proportion of each genome derived from 
several putative ‘ancestral populations’ (Fig. 2a and Extended Data Fig. 5). This analysis 
separates continental groups, highlights their internal substructure, and reveals genetic 
similarities between related populations. For example, east–west clines are visible in Africa 
and East Asia, a north–south cline is visible in Europe, and European, African, and Native-
American admixture is visible in genomes sampled in the Americas.
To characterize more recent patterns of shared ancestry, we first focused on variants 
observed on just two chromosomes (sample frequency of 0.04%), the rarest shared variants 
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within our sample, and known as f2 variants2. As expected, these variants are typically 
geographically restricted and much more likely to be shared between individuals in the same 
population or continental group, or between populations with known recent admixture 
(Extended Data Fig. 6a, b). Analysis of shared haplotype lengths around f2 variants suggests 
a median common ancestor ~296 generations ago (7,410 to 8,892 years ago; Extended Data 
Fig. 6c, d), although those confined within a population tend to be younger, with a shared 
common ancestor ~143 generations ago (3,570 to 4,284 years ago)13.
Insights about demography
Modelling the distribution of variation within and between genomes can provide insights 
about the history and demography of our ancestor populations14. We used the pairwise 
sequentially Markovian coalescent (PSMC)14 method to characterize the effective 
population size (Ne) of the ancestral populations (Fig. 2b and Extended Data Fig. 7). Our 
results show a shared demographic history for all humans beyond ~150,000 to 200,000 years 
ago. Further, they show that European, Asian and American populations shared strong and 
sustained bottlenecks, all with Ne < 1,500, between 15,000 to 20,000 years ago. In contrast, 
the bottleneck experienced by African populations during the same time period appears less 
severe, with Ne > 4,250. These bottlenecks were followed by extremely rapid inferred 
population growth in non-African populations, with notable exceptions including the PEL, 
MXL and FIN.
Due to the shared ancestry of all humans, only a modest number of variants show large 
frequency differences among populations. We observed 762,000 variants that are rare 
(defined as having frequency <0.5%) within the global sample but much more common 
(>5% frequency) in at least one population (Fig. 3a). Several populations have relatively 
large numbers of these variants, and these are typically genetically or geographically distinct 
within their continental group (LWK in Africa, PEL in the Americas, JPT in East Asia, FIN 
in Europe, and GIH in South Asia; see Supplementary Table 5). Drifted variants within such 
populations may reveal phenotypic associations that would be hard to identify in much 
larger global samples15.
Analysis of the small set of variants with large frequency differences between closely related 
populations can identify targets of recent, localized adaptation. We used the FST-based 
population branch statistic (PBS)16 to identify genes with strong differentiation between 
pairs of populations in the same continental group (Fig. 3b). This approach reveals a number 
of previously identified selection signals (such as SLC24A5 associated with skin 
pigmentation17, HERC2 associated with eye colour18, LCT associated with lactose tolerance, 
and the FADS cluster that may be associated with dietary fat sources19). Several potentially 
novel selection signals are also highlighted (such as TRBV9, which appears particularly 
differentiated in South Asia, PRICKLE4, differentiated in African and South Asian 
populations, and a number of genes in the immunoglobulin cluster, differentiated in East 
Asian populations; Extended Data Fig. 8), although at least some of these signals may result 
from somatic rearrangements (for example, via V(D)J recombination) and differences in cell 
type composition among the sequenced samples. Nonetheless, the relatively small number of 
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genes showing strong differentiation between closely related populations highlights the 
rarity of strong selective sweeps in recent human evolution20.
Sharing of haplotypes and imputation
The sharing of haplotypes among individuals is widely used for imputation in GWAS, a 
primary use of 1000 Genomes data. To assess imputation based on the phase 3 data set, we 
used Complete Genomics data for 9 or 10 individuals from each of 6 populations (CEU, 
CHS, LWK, PEL, PJL, and YRI). After excluding these individuals from the reference 
panel, we imputed genotypes across the genome using sites on a typical one million SNP 
microarray. The squared correlation between imputed and experimental genotypes was 
>95% for common variants in each population, decreasing gradually with minor allele 
frequency (Fig. 4a). Compared to phase 1, rare variation imputation improved considerably, 
particularly for newly sampled populations (for example, PEL and PJL, Extended Data Fig. 
9a). Improvements in imputations restricted to overlapping samples suggest approximately 
equal contributions from greater genotype and sequence quality and from increased sample 
size (Fig. 4a, inset). Imputation accuracy is now similar for bi-allelic SNPs, bi-allelic indels, 
multi-allelic SNPs, and sites where indels and SNPs overlap, but slightly reduced for multi-
allelic indels, which typically map to regions of low-complexity sequence and are much 
harder to genotype and phase (Extended Data Fig. 9b). Although imputation of rare variation 
remains challenging, it appears to be most accurate in African ancestry populations, where 
greater genetic diversity results in a larger number of haplotypes and improves the chances 
that a rare variant is tagged by a characteristic haplotype.
Resolution of genetic association studies
To evaluate the impact of our new reference panel on GWAS, we re-analysed a previous 
study of age-related macular degeneration (AMD) totalling 2,157 cases and 1,150 
controls21. We imputed 17.0 million genetic variants with estimated R2 > 0.3, compared to 
14.1 million variants using phase 1, and only 2.4 million SNPs using HapMap2. Compared 
to phase 1, the number of imputed common and intermediate frequency variants increased 
by 7%, whereas the number of rare variants increased by >50%, and the number of indels 
increased by 70% (Supplementary Table 6). We permuted case-control labels to estimate a 
genome-wide significance threshold of P < ~1.5 × 10−8, which corresponds to ~3 million 
independent variants and is more stringent than the traditional threshold of 5 × 10−8 
(Supplementary Table 7). In practice, significance thresholds must balance false positives 
and false negatives22–24. We recommend that thresholds aiming for strict control of false 
positives should be determined using permutations. We expect thresholds to become more 
stringent when larger sample sizes are sequenced, when diverse samples are studied, or 
when genotyping and imputation is replaced with direct sequencing. After imputation, five 
independent signals in four previously reported AMD loci25–28 reached genome-wide 
significance (Supplementary Table 8). When we examined each of these to define a set of 
potentially causal variants using a Bayesian Credible set approach29, lists of potentially 
functional variants were ~4× larger than in HapMap2-based analysis and 7% larger than in 
analyses based on phase 1 (Supplementary Table 9). In the ARMS2/HTRA1 locus, the most 
strongly associated variant was now a structural variant (estimated imputation R2 = 0.89) 
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that previously could not be imputed, consistent with some functional studies30. Deep 
catalogues of potentially functional variants will help ensure that downstream functional 
analyses include the true candidate variants, and will aid analyses that integrate complex 
disease associations with functional genomic elements31.
The performance of imputation and GWAS studies depends on the local distribution of 
linkage disequilibrium (LD) between nearby variants. Controlling for sample size, the decay 
of LD as a function of physical distance is fastest in African populations and slowest in East 
Asian populations (Extended Data Fig. 10). To evaluate how these differences influence the 
resolution of genetic association studies and, in particular, their ability to identify a narrow 
set of candidate functional variants, we evaluated the number of tagging variants (r2 > 0.8) 
for a typical variant in each population. We find that each common variant typically has 
over 15–20 tagging variants in non-African populations, but only about 8 in African 
populations (Fig. 4b). At lower frequencies, we find 3–6 tagging variants with 100 kb of 
variants with frequency <0.5%, and differences in the number of tagging variants between 
continental groups are less marked.
Among variants in the GWAS catalogue (which have an average frequency of 26.6% in 
project haplotypes), the number of proxies averages 14.4 in African populations and 30.3–
44.4 in other continental groupings (Supplementary Table 10). The potential value of multi-
population fine-mapping is illustrated by the observation that the number of proxies shared 
across all populations is only 8.2 and, furthermore, that 34.9% of GWAS catalogue variants 
have no proxy shared across all continental groupings.
To further assess prospects for fine-mapping genetic association signals, we performed 
expression quantitative trait loci (eQTL) discovery at 17,667 genes in 69 samples from each 
of 6 populations (CEU, CHB, GIH, JPT, LWK, and YRI)32. We identified eQTLs for 3,285 
genes at 5% FDR (average 1,265 genes per population). Overall, a typical eQTL signal 
comprised 67 associated variants, including an indel as one of the top associated variants 
26–40% of the time (Fig. 4c). Within each discovery population, 17.5–19.5% of top eQTL 
variants overlapped annotated transcription factor binding sites (TFBSs), consistent with the 
idea that a substantial fraction of eQTL polymorphisms are TFBS polymorphisms. Using a 
meta-analysis approach to combine pairs of populations, the proportion of top eQTL variants 
overlapping TFBSs increased to 19.2–21.6% (Fig. 4d), consistent with improved 
localization. Including an African population provided the greatest reduction in the count of 
associated variants and the greatest increase in overlap between top variants and TFBSs.
Discussion
Over the course of the 1000 Genomes Project there have been substantial advances in 
sequence data generation, archiving and analysis. Primary sequence data production 
improved with increased read length and depth, reduced per-base errors, and the 
introduction of paired-end sequencing. Sequence analysis methods improved with the 
development of strategies for identifying and filtering poor-quality data, for more accurate 
mapping of sequence reads (particularly in repetitive regions), for exchanging data between 
analysis tools and enabling ensemble analyses, and for capturing more diverse types of 
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variants. Importantly, each release has examined larger numbers of individuals, aiding 
population-based analyses that identify and leverage shared haplotypes during genotyping. 
Whereas our first analyses produced high-confidence short-variant calls for 80–85% of the 
reference genome1, our newest analyses reach ~96% of the genome using the same metrics, 
although our ability to accurately capture structural variation remains more limited33. In 
addition, the evolution of sequencing, analysis and filtering strategies means that our results 
are not a simple superset of previous analysis. Although the number of characterized 
variants has more than doubled relative to phase 1, ~2.3 million previously described 
variants are not included in the current analysis; most missing variants were rare or marked 
as low quality: 1.6 million had frequency <0.5% and may be missing from our current read 
set, while the remainder were removed by our filtering processes.
These same technical advances are enabling the application of whole genome sequencing to 
a variety of medically important samples. Some of these studies already exceed the 1000 
Genomes Project in size34–36, but the results described here remain a prime resource for 
studies of genetic variation for several reasons. First, the 1000 Genomes Project samples 
provide a broad representation of human genetic variation—in contrast to the bulk of 
complex disease studies in humans, which primarily study European ancestry samples and 
which, as we show, fail to capture functionally important variation in other populations. 
Second, the project analyses incorporate multiple analysis strategies, callsets and variant 
types. Although such ensemble analyses are cumbersome, they provide a benchmark for 
what can be achieved and a yardstick against which more practical analysis strategies can be 
evaluated. Third, project samples and data resulting from them can be shared broadly, 
enabling sequencing strategies and analysis methods to be compared easily on a benchmark 
set of samples. Because of the wide availability of the data and samples, these samples have 
been and will continue to be used for studying many molecular phenotypes. Thus, we 
predict that the samples will accumulate many types of data that will allow connections to be 
drawn between variants and both molecular and disease phenotypes.
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Extended Data
Extended Data Figure 1. Summary of the callset generation pipeline
Boxes indicate steps in the process and numbers indicate the corresponding section(s) within 
the Supplementary Information.
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Extended Data Figure 2. Power of discovery and heterozygote genotype discordance
a, The power of discovery within the main data set for SNPs and indels identified within an 
overlapping sample of 284 genomes sequenced to high coverage by Complete Genomics 
(CG), and against a panel of >60,000 haplotypes constructed by the Haplotype Reference 
Consortium (HRC)9. To provide a measure of uncertainty, one curve is plotted for each 
chromosome. b, Improved power of discovery in phase 3 compared to phase 1, as assessed 
in a sample of 170 Complete Genomics genomes that are included in both phase 1 and phase 
3. c, Heterozygote discordance in phase 3 for SNPs, indels, and SVs compared to 284 
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Complete Genomics genomes. d, Heterozygote discordance for phase 3 compared to phase 1 
within the intersecting sample. e, Sensitivity to detect Complete Genomics SNPs as a 
function of sequencing depth. f, Heterozygote genotype discordance as a function of 
sequencing depth, as compared to Complete Genomics data.
Extended Data Figure 3. Variant counts
a, The number of variants within the phase 3 sample as a function of alternative allele 
frequency. b, The average number of detected variants per genome with whole-sample allele 
frequencies <0.5% (grey bars), with the average number of singletons indicated by colours.
Extended Data Figure 4. The standardized number of variant sites per genome, partitioned by 
population and variant category
For each category, z-scores were calculated by subtracting the mean number of sites per 
genome (calculated across the whole sample), and dividing by the standard deviation. From 
left: sites with a derived allele, synonymous sites with a derived allele, nonsynonymous sites 
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with a derived allele, sites with a loss-of-function allele, sites with a HGMD disease 
mutation allele, sites with a ClinVar pathogenic variant, and sites carrying a GWAS risk 
allele.
Extended Data Figure 5. Population structure as inferred using the admixture program for K = 5 
to 12
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Extended Data Figure 6. Allelic sharing
a, Genotype covariance (above diagonal) and sharing of f2 variants (below diagonal) 
between pairs of individuals. b, Quantification of average f2 sharing between populations. 
Each row represents the distribution of f2 variants shared between individuals from the 
population indicated on the left to individuals from each of the sampled populations. c, The 
average number of f2 variants per haploid genome. d, The inferred age of f2 variants, as 
estimated from shared haplotype lengths, with black dots indicating the median value.
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Extended Data Figure 7. Unsmoothed PSMC curves
a, The median PSMC curve for each population. b, PSMC curves estimated separately for 
all individuals within the 1000 Genomes sample. c, Unsmoothed PSMC curves comparing 
estimates from the low coverage data (dashed lines) to those obtained from high coverage 
PCR-free data (solid lines). Notable differences are confined to very recent time intervals, 
where the additional rare variants identified by deep sequencing suggest larger population 
sizes.
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Extended Data Figure 8. Genes showing very strong patterns of differentiation between pairs of 
closely related populations within each continental group
Within each continental group, the maximum PBS statistic was selected from all pairwise 
population comparisons within the continental group against all possible out-of-continent 
populations. Note the x axis shows the number of polymorphic sites within the maximal 
comparison.
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Extended Data Figure 9. Performance of imputation
a, Performance of imputation in 6 populations using a subset of phase 3 as a reference panel 
(n = 2,445), phase 1 (n = 1,065), and the corresponding data within intersecting samples 
from both phases (n = 1,006). b, Performance of imputation from phase 3 by variant class.
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Extended Data Figure 10. Decay of linkage disequilibrium as a function of physical distance
Linkage disequilibrium was calculated around 10,000 randomly selected polymorphic sites 
in each population, having first thinned each population down to the same sample size (61 
individuals). The plotted line represents a 5 kb moving average.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The 1000 Genomes Project Consortium (Participants are arranged by project role, then by 
institution alphabetically, and finally alphabetically within institutions except for Principal 
Investigators and Project Leaders, as indicated.)
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Steering committee: David M. Altshuler3 (Co-Chair), Richard M. Durbin4 (Co-Chair), 
Gonçalo R. Abecasis2, David R. Bentley5, Aravinda Chakravarti6, Andrew G. Clark7, Peter 
Donnelly8,9, Evan E. Eichler10,11, Paul Flicek12, Stacey B. Gabriel13, Richard A. Gibbs14, 
Eric D. Green15, Matthew E. Hurles4, Bartha M. Knoppers16, Jan O. Korbel12,17, Eric S. 
Lander13, Charles Lee18,19, Hans Lehrach20,21, Elaine R. Mardis22, Gabor T. Marth23, Gil 
A. McVean8,9, Deborah A. Nickerson10, Jeanette P. Schmidt24, Stephen T. Sherry25, Jun 
Wang26,27,28,29,30, Richard K. Wilson22
Production group: Baylor College of Medicine Richard A. Gibbs14 (Principal 
Investigator), Eric Boerwinkle14, Harsha Doddapaneni14, Yi Han14, Viktoriya Korchina14, 
Christie Kovar14, Sandra Lee14, Donna Muzny14, Jeffrey G. Reid14, Yiming Zhu14; BGI-
Shenzhen Jun Wang26,27,28,29,30 (Principal Investigator), Yuqi Chang26, Qiang Feng26,27, 
Xiaodong Fang26,27, Xiaosen Guo26,27, Min Jian26,27, Hui Jiang26,27, Xin Jin26, Tianming 
Lan26, Guoqing Li26, Jingxiang Li26, Yingrui Li26, Shengmao Liu26, Xiao Liu26,27, Yao 
Lu26, Xuedi Ma26, Meifang Tang26, Bo Wang26, Guangbiao Wang26, Honglong Wu26, 
Renhua Wu26, Xun Xu26, Ye Yin26, Dandan Zhang26, Wenwei Zhang26, Jiao Zhao26, Meiru 
Zhao26, Xiaole Zheng26; Broad Institute of MIT and Harvard Eric S. Lander13 (Principal 
Investigator), David M. Altshuler3, Stacey B. Gabriel13 (Co-Chair), Namrata Gupta13; 
Coriell Institute for Medical Research Neda Gharani31, Lorraine H. Toji31, Norman P. 
Gerry31, Alissa M. Resch31; European Molecular Biology Laboratory, European 
Bioinformatics Institute Paul Flicek12 (Principal Investigator), Jonathan Barker12, Laura 
Clarke12, Laurent Gil12, Sarah E. Hunt12, Gavin Kelman12, Eugene Kulesha12, Rasko 
Leinonen12, William M. McLaren12, Rajesh Radhakrishnan12, Asier Roa12, Dmitriy 
Smirnov12, Richard E. Smith12, Ian Streeter12, Anja Thormann12, Iliana Toneva12, Brendan 
Vaughan12, Xiangqun Zheng-Bradley12; Illumina David R. Bentley5 (Principal 
Investigator), Russell Grocock5, Sean Humphray5, Terena James5, Zoya Kingsbury5; Max 
Planck Institute for Molecular Genetics Hans Lehrach20,21 (Principal Investigator), Ralf 
Sudbrak32 (Project Leader), Marcus W. Albrecht33, Vyacheslav S. Amstislavskiy20, Tatiana 
A. Borodina33, Matthias Lienhard20, Florian Mertes20, Marc Sultan20, Bernd 
Timmermann20, Marie-Laure Yaspo20; McDonnell Genome Institute at Washington 
University Elaine R. Mardis22 (Co-Principal Investigator) (Co-Chair), Richard K. Wilson22 
(Co-Principal Investigator), Lucinda Fulton22, Robert Fulton22; US National Institutes of 
Health Stephen T. Sherry25 (Principal Investigator), Victor Ananiev25, Zinaida Belaia25, 
Dimitriy Beloslyudtsev25, Nathan Bouk25, Chao Chen25, Deanna Church34, Robert 
Cohen25, Charles Cook25, John Garner25, Timothy Hefferon25, Mikhail Kimelman25, 
Chunlei Liu25, John Lopez25, Peter Meric25, Chris O’Sullivan35, Yuri Ostapchuk25, Lon 
Phan25, Sergiy Ponomarov25, Valerie Schneider25, Eugene Shekhtman25, Karl Sirotkin25, 
Douglas Slotta25, Hua Zhang25; University of Oxford Gil A. McVean8,9 (Principal 
Investigator); Wellcome Trust Sanger Institute Richard M. Durbin4 (Principal 
Investigator), Senduran Balasubramaniam4, John Burton4, Petr Danecek4, Thomas M. 
Keane4, Anja Kolb-Kokocinski4, Shane McCarthy4, James Stalker4, Michael Quail4
Analysis group: Affymetrix Jeanette P. Schmidt24 (Principal Investigator), Christopher J. 
Davies24, Jeremy Gollub24, Teresa Webster24, Brant Wong24, Yiping Zhan24; Albert 
Einstein College of Medicine Adam Auton1 (Principal Investigator), Christopher L. 
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Campbell1, Yu Kong1, Anthony Marcketta1; Baylor College of Medicine Richard A. 
Gibbs14 (Principal Investigator), Fuli Yu14 (Project Leader), Lilian Antunes14, Matthew 
Bainbridge14, Donna Muzny14, Aniko Sabo14, Zhuoyi Huang14; BGI-Shenzhen Jun 
Wang26,27,28,29,30 (Principal Investigator), Lachlan J. M. Coin26, Lin Fang26,27, Xiaosen 
Guo26, Xin Jin26, Guoqing Li26, Qibin Li26, Yingrui Li26, Zhenyu Li26, Haoxiang Lin26, 
Binghang Liu26, Ruibang Luo26, Haojing Shao26, Yinlong Xie26, Chen Ye26, Chang Yu26, 
Fan Zhang26, Hancheng Zheng26, Hongmei Zhu26; Bilkent University Can Alkan36, 
ElifDal36, Fatma Kahveci36; Boston College Gabor T. Marth23 (Principal Investigator), Erik 
P. Garrison4 (Project Lead), Deniz Kural37, Wan-Ping Lee37, Wen Fung Leong38, Michael 
Stromberg39, Alistair N. Ward23, Jiantao Wu39, Mengyao Zhang40; Broad Institute of MIT 
and Harvard Mark J. Daly13 (Principal Investigator), Mark A. DePristo41 (Project Leader), 
Robert E. Handsaker13,40 (Project Leader), David M. Altshuler3, Eric Banks13, Gaurav 
Bhatia13, Guillermo del Angel13, Stacey B. Gabriel13, Giulio Genovese13, Namrata Gupta13, 
Heng Li13, Seva Kashin13,40, Eric S. Lander13, Steven A. McCarroll13,40, James C. 
Nemesh13, Ryan E. Poplin13; Cold Spring Harbor Laboratory Seungtai C. Yoon42 
(Principal Investigator), Jayon Lihm42, Vladimir Makarov43; Cornell University Andrew 
G. Clark7 (Principal Investigator), Srikanth Gottipati44, Alon Keinan7, Juan L. Rodriguez-
Flores45; European Molecular Biology Laboratory Jan O. Korbel12,17 (Principal 
Investigator), Tobias Rausch17,46 (Project Leader), Markus H. Fritz46, Adrian M. Stütz17; 
European Molecular Biology Laboratory, European Bioinformatics Institute Paul 
Flicek12 (Principal Investigator), Kathryn Beal12, Laura Clarke12, Avik Datta12, Javier 
Herrero47, William M. McLaren12, Graham R. S. Ritchie12, Richard E. Smith12, Daniel 
Zerbino12, Xiangqun Zheng-Bradley12; Harvard University Pardis C. Sabeti13,48 (Principal 
Investigator), Ilya Shlyakhter13,48, Stephen F. Schaffner13,48, Joseph Vitti13,49; Human 
Gene Mutation Database David N. Cooper50 (Principal Investigator), Edward V. Ball50, 
Peter D. Stenson50; Illumina David R. Bentley5 (Principal Investigator), Bret Barnes39, 
Markus Bauer5, R. Keira Cheetham5, Anthony Cox5, Michael Eberle5, Sean Humphray5, 
Scott Kahn39, Lisa Murray5, John Peden5, Richard Shaw5; Icahn School of Medicine at 
Mount Sinai Eimear E. Kenny51 (Principal Investigator); Louisiana State University Mark 
A. Batzer52 (Principal Investigator), Miriam K. Konkel52, Jerilyn A. Walker52; 
Massachusetts General Hospital Daniel G. MacArthur53 (Principal Investigator), Monkol 
Lek53; Max Planck Institute for Molecular Genetics Ralf Sudbrak32 (Project Leader), 
Vyacheslav S. Amstislavskiy20, Ralf Herwig20; McDonnell Genome Institute at 
Washington University Elaine R. Mardis22 (Co-Principal Investigator), Li Ding22, Daniel 
C. Koboldt22, David Larson22, Kai Ye22; McGill University Simon Gravel54; National Eye 
Institute, NIH Anand Swaroop55, Emily Chew55; New York Genome Center Tuuli 
Lappalainen56,57 (Principal Investigator), Yaniv Erlich56,58 (Principal Investigator), Melissa 
Gymrek13,56,59,60, Thomas Frederick Willems61; Ontario Institute for Cancer Research 
Jared T. Simpson62; Pennsylvania State University Mark D. Shriver63 (Principal 
Investigator); Rutgers Cancer Institute of New Jersey Jeffrey A. Rosenfeld64 (Principal 
Investigator); Stanford University Carlos D. Bustamante65 (Principal Investigator), 
Stephen B. Montgomery66 (Principal Investigator), Francisco M. De La Vega65 (Principal 
Investigator), Jake K. Byrnes67, Andrew W. Carroll68, Marianne K. DeGorter66, Phil 
Lacroute65, Brian K. Maples65, Alicia R. Martin65, Andres Moreno-Estrada65,69, Suyash S. 
Shringarpure65, Fouad Zakharia65; Tel-Aviv University Eran Halperin70,71,72 (Principal 
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Investigator), Yael Baran70; The Jackson Laboratory for Genomic Medicine Charles 
Lee18,19 (Principal Investigator), Eliza Cerveira18, Jaeho Hwang18, Ankit Malhotra18 (Co-
Project Lead), Dariusz Plewczynski18, Kamen Radew18, Mallory Romanovitch18, 
Chengsheng Zhang18 (Co-Project Lead); Thermo Fisher Scientific Fiona C. L. Hyland73; 
Translational Genomics Research Institute David W. Craig74 (Principal Investigator), 
Alexis Christoforides74, Nils Homer75, Tyler Izatt74, Ahmet A. Kurdoglu74, Shripad A. 
Sinari74, Kevin Squire76; US National Institutes of Health Stephen T. Sherry25 (Principal 
Investigator), Chunlin Xiao25; University of California, San Diego Jonathan Sebat77,78 
(Principal Investigator), Danny Antaki77, Madhusudan Gujral77, Amina Noor77, Kenny 
Ye79; University of California, San Francisco Esteban G. Burchard80 (Principal 
Investigator), Ryan D. Hernandez80,81,82 (Principal Investigator), Christopher R. Gignoux80; 
University of California, Santa Cruz David Haussler83,84 (Principal Investigator), Sol J. 
Katzman83, W. James Kent83; University of Chicago Bryan Howie85; University College 
London Andres Ruiz-Linares86 (Principal Investigator); University of Geneva Emmanouil 
T. Dermitzakis87,88,89 (Principal Investigator); University of Maryland School of 
Medicine Scott E. Devine90 (Principal Investigator); University of Michigan Gonçalo R. 
Abecasis2 (Principal Investigator) (Co-Chair), Hyun Min Kang2 (Project Leader), Jeffrey M. 
Kidd91,92 (Principal Investigator), Tom Blackwell2, Sean Caron2, Wei Chen93, Sarah 
Emery92, Lars Fritsche2, Christian Fuchsberger2, Goo Jun2,94, Bingshan Li95, Robert 
Lyons96, Chris Scheller2, Carlo Sidore2,97,98, Shiya Song91, Elzbieta Sliwerska92, Daniel 
Taliun2, Adrian Tan2, Ryan Welch2, Mary Kate Wing2, Xiaowei Zhan99; University of 
Montréal Philip Awadalla62,100 (Principal Investigator), Alan Hodgkinson100; University 
of North Carolina at Chapel Hill Yun Li101; University of North Carolina at Charlotte 
Xinghua Shi102 (Principal Investigator), Andrew Quitadamo102; University of Oxford 
Gerton Lunter8 (Principal Investigator), Gil A. McVean8,9 (Principal Investigator) (Co-
Chair), Jonathan L. Marchini8,9 (Principal Investigator), Simon Myers8,9 (Principal 
Investigator), Claire Churchhouse9, Olivier Delaneau9,87, Anjali Gupta-Hinch8, Warren 
Kretzschmar8, Zamin Iqbal8, Iain Mathieson8, Androniki Menelaou9,103, Andy Rimmer87, 
Dionysia K. Xifara8,9; University of Puerto Rico Taras K. Oleksyk104 (Principal 
Investigator); University of Texas Health Sciences Center at Houston Yunxin Fu94 
(Principal Investigator), Xiaoming Liu94, Momiao Xiong94; University of Utah Lynn 
Jorde105 (Principal Investigator), David Witherspoon105, Jinchuan Xing106; University of 
Washington Evan E. Eichler10,11 (Principal Investigator), Brian L. Browning107 (Principal 
Investigator), Sharon R. Browning108 (Principal Investigator), Fereydoun Hormozdiari10, 
Peter H. Sudmant10; Weill Cornell Medical College, Ekta Khurana109 (Principal 
Investigator); Wellcome Trust Sanger Institute Richard M. Durbin4 (Principal 
Investigator), Matthew E. Hurles4 (Principal Investigator), Chris Tyler-Smith4 (Principal 
Investigator), Cornelis A. Albers110,111, Qasim Ayub4, Senduran Balasubramaniam4, Yuan 
Chen4, Vincenza Colonna4,112, Petr Danecek4, Luke Jostins8, Thomas M. Keane4, Shane 
McCarthy4, Klaudia Walter4, Yali Xue4; Yale University Mark B. Gerstein113,114,115 
(Principal Investigator), Alexej Abyzov116, Suganthi Balasubramanian115, Jieming Chen113, 
Declan Clarke117, Yao Fu113, Arif O. Harmanci113, Mike Jin115, Donghoon Lee113, Jeremy 
Liu115, Xinmeng Jasmine Mu13,113, Jing Zhang113,115, Yan Zhang113,115
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Structural variation group: BGI-Shenzhen Yingrui Li26, Ruibang Luo26, Hongmei 
Zhu26; Bilkent University Can Alkan36, Elif Dal36, Fatma Kahveci36; Boston College 
Gabor T. Marth23 (Principal Investigator), Erik P. Garrison4, Deniz Kural37, Wan-Ping 
Lee37, Alistair N. Ward23, Jiantao Wu23, Mengyao Zhang23; Broad Institute of MIT and 
Harvard Steven A. McCarroll13,40 (Principal Investigator), Robert E. Handsaker13,40 
(Project Leader), David M. Altshuler3, Eric Banks13, Guillermo del Angel13, Giulio 
Genovese13, Chris Hartl13, Heng Li13, Seva Kashin13,40, James C. Nemesh13, Khalid 
Shakir13; Cold Spring Harbor Laboratory Seungtai C. Yoon42 (Principal Investigator), 
Jayon Lihm42, Vladimir Makarov43; Cornell University Jeremiah Degenhardt7; European 
Molecular Biology Laboratory Jan O. Korbel12,17 (Principal Investigator) (Co-Chair), 
Markus H. Fritz46, Sascha Meiers17, Benjamin Raeder17, Tobias Rausch17,46, Adrian M. 
Stütz17; European Molecular Biology Laboratory, European Bioinformatics Institute 
Paul Flicek12 (Principal Investigator), Francesco Paolo Casale12, Laura Clarke12, Richard E. 
Smith12, Oliver Stegle12, Xiangqun Zheng-Bradley12; Illumina David R. Bentley5 
(Principal Investigator), Bret Barnes39, R. Keira Cheetham5, Michael Eberle5, Sean 
Humphray5, Scott Kahn39, Lisa Murray5, Richard Shaw5; Leiden University Medical 
Center Eric-Wubbo Lameijer118; Louisiana State University Mark A. Batzer52 (Principal 
Investigator), Miriam K. Konkel52, Jerilyn A. Walker52; McDonnell Genome Institute at 
Washington University Li Ding22 (Principal Investigator), Ira Hall22, Kai Ye22; Stanford 
University Phil Lacroute65; The Jackson Laboratory for Genomic Medicine Charles 
Lee18,19 (Principal Investigator) (Co-Chair), Eliza Cerveira18, Ankit Malhotra18, Jaeho 
Hwang18, Dariusz Plewczynski18, Kamen Radew18, Mallory Romanovitch18, Chengsheng 
Zhang18; Translational Genomics Research Institute David W. Craig74 (Principal 
Investigator), Nils Homer75; US National Institutes of Health Deanna Church34, Chunlin 
Xiao25; University of California, San Diego Jonathan Sebat77 (Principal Investigator), 
Danny Antaki77, Vineet Bafna119, Jacob Michaelson120, Kenny Ye79; University of 
Maryland School of Medicine Scott E. Devine90 (Principal Investigator), Eugene J. 
Gardner90 (Project Leader); University of Michigan Gonçalo R. Abecasis2 (Principal 
Investigator), Jeffrey M. Kidd91,92 (Principal Investigator), Ryan E. Mills91,92 (Principal 
Investigator), Gargi Dayama91,92, Sarah Emery92, Goo Jun2,94; University of North 
Carolina at Charlotte Xinghua Shi102 (Principal Investigator), Andrew Quitadamo102; 
University of Oxford Gerton Lunter8 (Principal Investigator), Gil A. McVean8,9 (Principal 
Investigator); University of Texas MD Anderson Cancer Center Ken Chen121 (Principle 
Investigator), Xian Fan121, Zechen Chong121, Tenghui Chen121; University of Utah David 
Witherspoon105; Jinchuan Xing106; University of Washington Evan E. Eichler10,11 
(Principal Investigator) (Co-Chair), Mark J. Chaisson10, Fereydoun Hormozdiari10, John 
Huddleston10,11, Maika Malig10, Bradley J. Nelson10, Peter H. Sudmant10; Vanderbilt 
University School of Medicine Nicholas F. Parrish95; Weill Cornell Medical College Ekta 
Khurana109 (Principal Investigator); Wellcome Trust Sanger Institute Matthew E. Hurles4 
(Principal Investigator), Ben Blackburne4, Sarah J. Lindsay4, Zemin Ning4, Klaudia 
Walter4, Yujun Zhang4; Yale University Mark B. Gerstein113,114,115 (Principal 
Investigator), Alexej Abyzov116, Jieming Chen113, Declan Clarke117, Hugo Lam122, 
Xinmeng Jasmine Mu13,113, Cristina Sisu113, Jing Zhang113,115, Yan Zhang113,115
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Exome group: Baylor College of Medicine Richard A. Gibbs14 (Principal Investigator) 
(Co-Chair), Fuli Yu14 (Project Leader), Matthew Bainbridge14, Danny Challis14, Uday S. 
Evani14, Christie Kovar14, James Lu14, Donna Muzny14, Uma Nagaswamy14, Jeffrey G. 
Reid14, Aniko Sabo14, Jin Yu14; BGI-Shenzhen Xiaosen Guo26,27, Wangshen Li26, Yingrui 
Li26, Renhua Wu26; Boston College Gabor T. Marth23 (Principal Investigator) (Co-Chair), 
Erik P. Garrison4, Wen Fung Leong23, Alistair N. Ward23; Broad Institute of MIT and 
Harvard Guillermo del Angel13, Mark A. DePristo41, Stacey B. Gabriel13, Namrata 
Gupta13, Chris Hartl13, Ryan E. Poplin13; Cornell University Andrew G. Clark7 (Principal 
Investigator), Juan L. Rodriguez-Flores45; European Molecular Biology Laboratory, 
European Bioinformatics Institute Paul Flicek12 (Principal Investigator), Laura Clarke12, 
Richard E. Smith12, Xiangqun Zheng-Bradley12; Massachusetts General Hospital Daniel 
G. MacArthur53 (Principal Investigator); McDonnell Genome Institute at Washington 
University Elaine R. Mardis22 (Principal Investigator); Robert Fulton22, Daniel C. 
Koboldt22; McGill University Simon Gravel54; Stanford University Carlos D. 
Bustamante65 (Principal Investigator); Translational Genomics Research Institute David 
W. Craig74 (Principal Investigator), Alexis Christoforides74, Nils Homer75, Tyler Izatt74; US 
National Institutes of Health Stephen T. Sherry25 (Principal Investigator), Chunlin Xiao25; 
University of Geneva Emmanouil T. Dermitzakis87,88,89 (Principal Investigator); 
University of Michigan Gonçalo R. Abecasis2 (Principal Investigator), Hyun Min Kang2; 
University of Oxford Gil A. McVean8,9 (Principal Investigator); Yale University Mark B. 
Gerstein113,114,115 (Principal Investigator), Suganthi Balasubramanian115, Lukas 
Habegger113
Functional interpretation group: Cornell University Haiyuan Yu44 (Principal 
Investigator); European Molecular Biology Laboratory, European Bioinformatics 
Institute Paul Flicek12 (Principal Investigator), Laura Clarke12, Fiona Cunningham12, Ian 
Dunham12, Daniel Zerbino12, Xiangqun Zheng-Bradley12; Harvard University Kasper 
Lage13,123 (Principal Investigator), Jakob Berg Jespersen13,123,124, Heiko Horn13,123; 
Stanford University Stephen B. Montgomery66 (Principal Investigator), Marianne K. 
DeGorter66; Weill Cornell Medical College, Ekta Khurana109 (Principal Investigator); 
Wellcome Trust Sanger Institute Chris Tyler-Smith4 (Principal Investigator) (Co-Chair), 
Yuan Chen4, Vincenza Colonna4,112, Yali Xue4; Yale University Mark B. 
Gerstein113,1114,115 (Principal Investigator) (Co-Chair), Suganthi Balasubramanian115, Yao 
Fu113, Donghoon Kim115
Chromosome Y group: Albert Einstein College of Medicine Adam Auton1 (Principal 
Investigator), Anthony Marcketta1; American Museum of Natural History Rob 
Desalle125, Apurva Narechania126; Arizona State University Melissa A. Wilson Sayres127; 
Boston College Erik P. Garrison4; Broad Institute of MIT and Harvard Robert E. 
Handsaker13,40, Seva Kashin13,40, Steven A. McCarroll13,40; Cornell University: Juan L. 
Rodriguez-Flores45; European Molecular Biology Laboratory, European Bioinformatics 
Institute Paul Flicek12 (Principal Investigator), Laura Clarke12, Xiangqun Zheng-Bradley12; 
New York Genome Center Yaniv Erlich56,58, Melissa Gymrek13,56,59,60, Thomas 
Frederick Willems61; Stanford University Carlos D. Bustamante65 (Principal Investigator) 
(Co-Chair), Fernando L. Mendez65, G. David Poznik128, Peter A. Underhill65; The Jackson 
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Laboratory for Genomic Medicine Charles Lee18,19, Eliza Cerveira18, Ankit Malhotra18, 
Mallory Romanovitch18, Chengsheng Zhang18; University of Michigan Gonçalo R. 
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Wellcome Trust Sanger Institute Chris Tyler-Smith4 (Principal Investigator) (Co-Chair), 
Qasim Ayub4, Ruby Banerjee4, Maria Cerezo4, Yuan Chen4, Thomas W. Fitzgerald4, 
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Fengtang Yang4
Data coordination center group: Baylor College of Medicine Richard A. Gibbs14 
(Principal Investigator), Christie Kovar14, Divya Kalra14, Walker Hale14, Donna Muzny14, 
Jeffrey G. Reid14; BGI-Shenzhen Jun Wang26,27,28,29,30 (Principal Investigator), Xu Dan26, 
Xiaosen Guo26,27, Guoqing Li26, Yingrui Li26, Chen Ye26, Xiaole Zheng26; Broad Institute 
of MIT and Harvard David M. Altshuler3; European Molecular Biology Laboratory, 
European Bioinformatics Institute Paul Flicek12 (Principal Investigator) (Co-Chair), 
Laura Clarke12 (Project Lead), Xiangqun Zheng-Bradley12; Illumina David R. Bentley5 
(Principal Investigator), Anthony Cox5, Sean Humphray5, Scott Kahn39; Max Planck 
Institute for Molecular Genetics Ralf Sudbrak32 (Project Lead), Marcus W. Albrecht33, 
Matthias Lienhard20; McDonnell Genome Institute at Washington University David 
Larson22; Translational Genomics Research Institute David W. Craig74 (Principal 
Investigator), Tyler Izatt74, Ahmet A. Kurdoglu74; US National Institutes of Health 
Stephen T. Sherry25 (Principal Investigator) (Co-Chair), Chunlin Xiao25; University of 
California, Santa Cruz David Haussler83,84 (Principal Investigator); University of 
Michigan Gonçalo R. Abecasis2 (Principal Investigator); University of Oxford Gil A. 
McVean8,9 (Principal Investigator); Wellcome Trust Sanger Institute Richard M. Durbin4 
(Principal Investigator), Senduran Balasubramaniam4, Thomas M. Keane4, Shane 
McCarthy4, James Stalker4
Samples and ELSI group: Aravinda Chakravarti6 (Co-Chair), Bartha M. Knoppers16 (Co-
Chair), Gonçalo R. Abecasis2, Kathleen C. Barnes131, Christine Beiswanger31, Esteban G. 
Burchard80, Carlos D. Bustamante65, Hongyu Cai26, Hongzhi Cao26,27, Richard M. Durbin4, 
Norman P. Gerry31, Neda Gharani31, Richard A. Gibbs14, Christopher R. Gignoux80, Simon 
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BOX 1
Building a haplotype scaffold
To construct high quality haplotypes that integrate multiple variant types, we adopted a 
staged approach37. (1) A high-quality ‘haplotype scaffold’ was constructed using 
statistical methods applied to SNP microarray genotypes (black circles) and, where 
available, genotypes for first degree relatives (available for ~52% of samples; 
Supplementary Table 11)38. (2a) Variant sites were identified using a combination of 
bioinformatic tools and pipelines to define a set of high-confidence bi-allelic variants, 
including both SNPs and indels (white triangles), which were jointly imputed onto the 
haplotype scaffold. (2b) Multi-allelic SNPs, indels, and complex variants (represented by 
yellow shapes, or variation in copy number) were placed onto the haplotype scaffold one 
at a time, exploiting the local linkage disequilibrium information but leaving haplotypes 
for other variants undisturbed39. (3) The biallelic and multi-allelic haplotypes were 
merged into a single haplotype representation. This multi-stage approach allows the long-
range structure of the haplotype scaffold to be maintained while including more complex 
types of variation. Comparison to haplotypes constructed from fosmids suggests the 
average distance between phasing errors is ~1,062 kb, with typical phasing errors 
stretching ~37kb (Supplementary Table 12).
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Figure 1. Population sampling
a, Polymorphic variants within sampled populations. The area of each pie is proportional to 
the number of polymorphisms within a population. Pies are divided into four slices, 
representing variants private to a population (darker colour unique to population), private to 
a continental area (lighter colour shared across continental group), shared across continental 
areas (light grey), and shared across all continents (dark grey). Dashed lines indicate 
populations sampled outside of their ancestral continental region. b, The number of variant 
sites per genome. c, The average number of singletons per genome.
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Figure 2. Population structure and demography
a, Population structure inferred using a maximum likelihood approach with 8 clusters. b, 
Changes to effective population sizes over time, inferred using PSMC. Lines represent the 
within-population median PSMC estimate, smoothed by fitting a cubic spline passing 
through bin midpoints.
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Figure 3. Population differentiation
a, Variants found to be rare (<0.5%) within the global sample, but common (>5%) within a 
population. b, Genes showing strong differentiation between pairs of closely related 
populations. The vertical axis gives the maximum obtained value of the FST-based 
population branch statistic (PBS), with selected genes coloured to indicate the population in 
which the maximum value was achieved.
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Figure 4. Imputation and eQTL discovery
a, Imputation accuracy as a function of allele frequency for six populations. The insert 
compares imputation accuracy between phase 3 and phase 1, using all samples (solid lines) 
and intersecting samples (dashed lines). b, The average number of tagging variants (r2 > 
0.8) as a function of physical distance for common (top), low frequency (middle), and rare 
(bottom) variants. c, The proportion of top eQTL variants that are SNPs and indels, as 
discovered in 69 samples from each population. d, The percentage of eQTLs in TFBS, 
having performed discovery in the first population, and fine mapped by including an 
additional 69 samples from a second population (*P < 0.01, **P < 0.001, ***P < 0.0001, 
McNemar’s test). The diagonal represents the percentage of eQTLs in TFBS using the 
original discovery sample.
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